AKT1 and glioblastoma: LRRC4 deletion contributes to glioblastoma multiforme (GBM) malignant progression, while LRRC4 overexpression inhibits GBM cell proliferation and invasion by inhibiting the RTK/ERK/AKT/NF-kB signaling pathway (15–18).